减肥药概念股银诺医药-B(2591.HK)据报超购5364倍，超越蜜雪集团为今年超购王第二名！认购额涉资3700亿港元

Group 1 - The core viewpoint of the news is that Silverno Pharmaceuticals-B (2591.HK) has seen significant interest in its public offering, achieving an oversubscription rate of approximately 5,364 times, making it the second highest oversubscription this year after Mixue Group (2097.HK) [1] - The total subscription amount for Silverno Pharmaceuticals reached around HKD 370 billion, attracting approximately 260,000 investors [1] - The offering price for Silverno Pharmaceuticals was set at HKD 18.68, with a total fundraising target of HKD 683 million, and the stock is expected to be listed on Friday, August 15 [1]